Chlorpromazine Indications and Usage

Primary Psychiatric Indications

The American Academy of Pediatrics recommends chlorpromazine for the management of severe agitation and violent behavior, particularly in emergency settings 2
The American Psychiatric Association suggests that chlorpromazine is effective for treating acute episodes and preventing relapse in schizophrenia, with a recommended therapeutic dose equivalent to 600mg per day 3

Chlorpromazine is effective for treating intractable nausea and vomiting in various clinical scenarios, as recommended by the American Academy of Pediatrics 2
The American Academy of Pediatrics also recommends chlorpromazine as an adjunctive treatment for persistent hiccups unresponsive to other interventions 2

The American Academy of Pediatrics indicates that chlorpromazine is used for severe behavioral problems in children, though careful monitoring is required due to side effect profile 2
The American Society of Clinical Oncology suggests that chlorpromazine is used for sedation in management of refractory symptoms at end of life, with starting doses of 12.5mg every 4-12 hours (IV/IM) or 25-100mg every 4-12 hours (rectal) 1

The minimum effective dose of chlorpromazine for schizophrenia treatment is equivalent to 600mg per day, as recommended by the American Psychiatric Association 3
The American Society of Clinical Oncology suggests that for parenteral administration, 12.5mg every 4-12 hours IV/IM or 3-5mg/hour IV is used for acute agitation 1
The usual effective parenteral dose ranges from 37.5-150mg/day, as recommended by the American Society of Clinical Oncology 1

The European Society of Cardiology warns that chlorpromazine can cause QTc prolongation, potentially resulting in torsades de pointes, requiring ECG monitoring 4, 2
The American Society of Clinical Oncology notes that chlorpromazine is more likely to cause hypotension than some other antipsychotics (NNH 7) 1

The American Academy of Pediatrics advises to avoid co-administration of chlorpromazine with other QT-prolonging medications, as this increases risk of cardiac arrhythmias 2
The American Society of Clinical Oncology and the American Academy of Pediatrics warn that chlorpromazine can cause significant anticholinergic side effects, which may worsen conditions with anticholinergic properties 1, 2
Regular assessment of cardiovascular status, extrapyramidal symptoms, and metabolic parameters is essential, as recommended by the American Academy of Pediatrics 2
The American Psychiatric Association suggests that in treatment-resistant schizophrenia, chlorpromazine is not the preferred agent; clozapine should be considered after failure of at least two adequate antipsychotic trials 3, 5